Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer
NCT ID: NCT00899808
Last Updated: 2015-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at molecular markers and genetic markers in patients undergoing radiation therapy for cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
NCT00898430
Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer
NCT00899002
Biomarkers in Young Patients With Neuroblastoma
NCT01169376
DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers
NCT01139983
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
NCT02470819
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Determine local-regional control in patients undergoing radiation therapy for cancer, as a function of expression of specific molecular/genetic markers.
Secondary
* Determine complications of radiation therapy for patients undergoing radiation therapy for cancer.
OUTLINE: Previously collected tissue samples are analyzed using immunohistochemical staining and other molecular/genetic study methods to detect markers, including p53, cyclin D1, HER-2-neu, bcl-2/BAX, and EGFR. Patient charts are also reviewed with emphasis on local-regional relapse.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of cancer
* Undergoing radiation therapy for malignant disease
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Rutgers Cancer Institute of New Jersey
OTHER
Rutgers, The State University of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce G. Haffty, MD
Role: PRINCIPAL_INVESTIGATOR
Rutgers Cancer Institute of New Jersey- Robert Wood Johnson Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rutgers Cancer Institute of New Jersey - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000592887
Identifier Type: -
Identifier Source: secondary_id
CINJ-IRB-0220060141
Identifier Type: -
Identifier Source: secondary_id
000609
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.